Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical

Teva stock tumbled Wednesday after the company announced it would partner with Sanofi to develop an inflammatory bowel disease treatment.

Teva Pharma Hooks Sanofi In $1.5 Billion Inflammation Deal. But Shares Tumble.

Teva Pharmaceutical Industries Ltd.'s TEVA, -4.10% new collaboration with Sanofi SNY, on an inflammatory bowel disease treatment “will pay dividends” from a commercial perspective, Evercore ISI analysts wrote in a note Wednesday, as the companies team up on a therapy that's drawing growing investor interest.

Teva partnership with Sanofi ‘will pay dividends,' analyst says

Teva Pharmaceutical Industries said on Wednesday it will collaborate with French drugmaker Sanofi to co-develop its treatment for ulcerative colitis and Crohn's disease that it expects to ultimately be a blockbuster drug.

Sanofi to co-develop Teva Pharmaceutical's Colitis, Crohn's drug

PARIS & PARSIPPANY, N.J--(BUSINESS WIRE)--Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today a collaboration to co-develop and co-commercialize asset TEV ‘574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease. Paul Hudson Chief Executive Officer, Sanofi “Anti-TL1As are a promising class of therapies,.

Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Press Release - Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Johnson & Johnson

Sanofi revealed Tuesday that it had entered into an agreement with Janssen for the joint development and marketing of a vaccine candidate targeting extra-intestinal pathogenic E.coli.

Sanofi and Janssen join forces to develop E.coli vaccine, with Sanofi's $175M upfront payment

Sanofi on Tuesday announced it had reached an agreement with Janssen, a part of Johnson & Johnson , to develop and commercialize a vaccine candidate for extra-intestinal pathogenic E.coli.

Sanofi in agreement with Janssen to develop E. coli the vaccine candidate

British American Tobacco

Diageo

Novartis

SAP SE

TotalEnergies SE

It was nice while it lasted, but the AI-driven stock market rally is rapidly running out of gas.

The US Stock Market Could Crack in October: 6 ‘Strong Buy' European Dividend Aristocrats to Buy Now

If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.

FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE

Dupixent ® (dupilumab) sBLA for t reatment of e osinophilic e sophagitis in c hildren a ged 1 to 11 accepted for FDA Priority Review If approved, Dupixent would be the first and only treatment indicated in the U.S. for children aged 1- 11 with eosinophilic esophagitis, a disease driven by type 2 inflammation that impacts the ability to eat Of the approximately 21,000 children under the age of 12 in the U.S. currently being treated for EoE , about 9,000 do not satisfactorily respond to the unapproved therapies they have been treated with and potentially require advanced alternative therapy options Paris and Tarrytown, N.Y. September 26 , 2023.

Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review

Once-weekly ALTUVIIIO ® approved in Japan as a new class of factor VIII therapy for hemophilia A ALTUVIIIO is a first-in-class, high-sustained factor VIII replacement therapy which provides highly effective bleed protection in adults and children with hemophilia A Approval demonstrates commitment to delivering innovation and a paradigm shift in the hemophilia treatment landscape Paris , S ept ember 25 , 2023. The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorization for ALTUVIIIO®[Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein], a first-in-class, high-sustained factor VIII replacement therapy.

Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A

Availability of the Q 3 2023 Memorandum for modelling purposes Paris, France – September 2 2 , 2023. Sanofi announced today that its Q3 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/q3-results-2023 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results.

Press Release: Availability of the Q3 2023 Memorandum for modelling purposes

The French Pharma company is moving on an immunology franchise. Dupixent is the internal cash cow to drive lower debt and internal progress in the early-stage pipeline. Attractive valuation with a P/E discount and potential for upside driven by EPS momentum, new product launches, and pipeline success.

Sanofi: 3 Reasons For A Buy

National Grid

RELX

Are you looking for European stocks to buy? Bloomberg recently reported details about Bank of America's (NYSE: BAC ) latest survey of European fund managers.

3 Stocks to Buy to Ride Europe's Coming Market Surge

Sanofi support ing vulnerable communities as part of commitment to social impact and fight against climate change Paris, September 19 , 2023 – As global leaders gather at the United Nations' 78th General Assembly, Sanofi is delivering vital support to communities beset by climate turbulence and by unmet medical needs. These critical initiatives come as the global healthcare company confirms its commitment to positively impact society by tackl ing climate change and i ts consequences for human health.

Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change

BASILDON, England--(BUSINESS WIRE)--PRESS RELEASE – FOR TRADE, BUSINESS AND MEDICAL MEDIA ONLY Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi. The brands span four therapy areas of ongoing unmet need associated with CNS disor.

Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio From Sanofi

Pfizer

Pfizer and Sanofi both earned approval for RSV vaccines this year. This market alone won't be a major growth driver for these companies.

This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now

First Wave BioPharma

Shares of First Wave BioPharma Inc. FWBI, +8.61% soared 71.7% in active premarket trading Thursday, after the biopharmaceutical company announced an agreement to license Capeserod to Sanofi SNY, -0.73%, which First Wave will repurpose and develop for gastrointestinal indications. Trading volume swelled to 6.5 million shares, already more than double the full-day average of about 2.6 million shares, and enough to make the stock the third-most actively traded in Thursday's premarket.

First Wave BioPharma stock soars in active trading after Sanofi license deal

Certain groups are at an increased risk for serious complications from the flu, including adults 50 years of age and older and those with chronic health conditions. Sanofi's two higher-dose influenza vaccines, Fluzone® High-Dose Quadrivalent (Influenza Vaccine) and Flublok® Quadrivalent (Influenza Vaccine), have shown better flu protection than standard-dose flu shots in older adults.a,b BRIDGEWATER, N.J.

Sanofi and rapper/actor Ice-T unveil trailer for The Season as a warning against the flu

Adyen NV

Bayer AG

Anheuser-Busch InBev

GlaxoSmithKline

Imperial Brands PLC

JD.com

Omron Corp

Roche Holding AG

Tencent Holdings Limited

Taiwan Semiconductor Manufacturing

Yum China Hlds

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for.

International Wide-Moat Stocks On Sale - The September 2023 Heat Map

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?

Why Sanofi (SNY) is a Top Dividend Stock for Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Sanofi (SNY) is a Top Value Stock for the Long-Term

Sanofi announces changes to its Executive Committee Paris, August 31 st , 2023. Sanofi announces the following changes to its Executive Committee: Houman Ashrafian is appointed as Head of Research & Development, starting September 11th, 2023.

Press Release: Sanofi announces changes to its Executive Committee

Ambev

Assa Abloy AB

FANUC Corp

Novozymes A/S

Safran SA

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth it.

News for Sanofi Stock (SNY)